Labcorp Holdings Inc. LH
As ofNov 18, 2026, 9:41 AM EST
- YTD
- +45.43%
- 1 year
- +40.43%
- Market cap
- 29.58B
- Revenue (ttm)
- 14.59B
- Profit margin
- 6.88%
- EPS (ttm)
- 12.20
- Shares out
- 81.20M
- P/E ratio
- 29.86
- Forward P/E
- 18.78
- Dividend
- 2.88 (0.77%)
- Ex-dividend date
- Nov 24, 2026
- YTD return
- +45.43%
- 1-year return
- +40.43%
- Volume
- 19.66K
- Avg volume
- 740.18K
- Open
- 365.49
- Previous close
- 368.16
- Day's range
- 363.00 – 366.65
- 52-week range
- 250.39 – 372.46
- Beta
- 0.83
- Analysts
- Buy
- Price target
- 390.06 (+6.9%)
- Earnings date
- Feb 16, 2027
- 50-day average
- 330.55
5D -8.39 (-2.25%)
Key statistics
- 200-day average
- 292.91
- Enterprise value
- 36.85B
- PEG ratio
- 1.65
- Price / sales
- 2.05
- Price / book
- 3.38
- Payout ratio
- 23.61%
- Revenue growth
- 6.90%
- Free cash flow
- 1.06B
- Total cash
- 261.80M
- Total debt
- 6.85B
- Return on equity
- 11.44%
- Short % of float
- 3.14%
Fundamental scorecard
14 of 25 checks passed on LH’s reported financials
14of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 3 of 5
- Financial health 3 of 5
- Dividend 4 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 347.00
- Target (mean)
- 390.06
- Target (high)
- 420.00
- Strong buy2
- Buy11
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 4.51.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 4.50 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 4.64 | 4.78 | +0.14 | +3.02% |
| Jul 30, 2026 | Jun 30, 2026 | 4.78 | 4.99 | +0.21 | +4.39% |
| Apr 30, 2026 | Mar 31, 2026 | 4.11 | 4.25 | +0.14 | +3.41% |
| Feb 17, 2026 | Dec 31, 2025 | 3.95 | 4.07 | +0.12 | +3.04% |
| Oct 28, 2025 | Sep 30, 2025 | 4.13 | 4.18 | +0.05 | +1.21% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | UBS | main | Buy | Buy |
| Oct 29, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 29, 2026 | Truist Securities | main | Buy | Buy |
| Oct 29, 2026 | Baird | main | Outperform | Outperform |
| Sep 21, 2026 | Truist Securities | main | Buy | Buy |
| Sep 11, 2026 | UBS | main | Buy | Buy |
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- labcorp.com
News
OTraces Selects Labcorp To Perform Reference Laboratory Testing For Florida Department Of Health–Funded Clinical Trial Evaluating OTraces Blood-Based Prostate Cancer Diagnostic Platform
OTraces Selects Labcorp to Perform Biomarker Testing for Florida Department of Health–Funded Prostate Cancer Study Labcorp Collaborates With Grupo Fleury To Expand Clinical Trial Operations In Brazil
Labcorp to Expand Clinical Trial Operations in Brazil with Dedicated Kit Assembly and Future Laboratory Operations through Collaboration with Grupo Fleury
Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term
Labcorp (NYSE:LH) EVP Sells $744,080.00 in Stock
Labcorp Holdings Inc. $LH Stock Sold by Eurizon Capital SGR S.p.A.
Fifth Third Bancorp Sells 6,956 Shares of Labcorp Holdings Inc. $LH
Labcorp's Lab Growth Surges as $125 Million Reimbursement Risk Looms
Labcorp: 3 Key Takeaways for Long-Term Investors
Your note
Sign in to keep a note on LH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON KERRII B | Director | Sale | Aug 16, 2026 | 6,851 |
| BERBERIAN LANCE V | Officer | Stock Award(Grant) | Mar 26, 2025 | 18,652 |
| CAVENEY BRIAN J | Officer | Sale | Nov 9, 2026 | 34,562 |
| EISENBERG GLENN A | Officer | Stock Award(Grant) | Mar 26, 2025 | 37,920 |
| KONG GARHENG | Director | Conversion of Exercise of derivative security | Feb 10, 2026 | 13,739 |
| NEUPERT PETER M | Director | Conversion of Exercise of derivative security | Feb 10, 2026 | 13,784 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.05% | 6,535,506 | 2.41B | Sep 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 5,309,930 | 1.95B | Sep 29, 2026 |
| State Street Corporation | 4.86% | 3,943,551 | 1.45B | Sep 29, 2026 |
| Victory Capital Management Inc. | 4.83% | 3,918,578 | 1.44B | Sep 29, 2026 |
| FMR, LLC | 4.54% | 3,689,552 | 1.36B | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 4.46% | 3,618,770 | 1.33B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.21% | 2,603,810 | 958.62M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.62% | 2,124,615 | 782.20M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.19% | 1,776,838 | 654.16M | Jun 29, 2026 |
| ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund | 1.80% | 1,462,400 | 538.40M | Sep 29, 2026 |
| Victory Portfolios-Victory Sycamore Established Value Fund | 1.78% | 1,445,000 | 531.99M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 1,080,629 | 397.84M | Sep 29, 2026 |
